The clinical management of BRCA1 and BRCA2 mutation carriers

@article{Gulati2006TheCM,
  title={The clinical management of BRCA1 and BRCA2 mutation carriers},
  author={A. P. Gulati and S. Domchek},
  journal={Current Oncology Reports},
  year={2006},
  volume={10},
  pages={47-53}
}
  • A. P. Gulati, S. Domchek
  • Published 2006
  • Medicine
  • Current Oncology Reports
    • Mutations in the cancer susceptibility genes BRCA1 and BRCA2 are associated with significantly increased risks of breast and ovarian cancer. Fortunately, effective strategies are available to reduce these risks, including genetic testing, which is an important consideration in determining management of patients with a strong family history of cancer. This article reviews the current evidence for risk-reducing strategies in BRCA1 and BRCA2 mutation carriers and outlines future research… CONTINUE READING
    View on Springer
    ncbi.nlm.nih.gov
    9 Citations
    Highly Influencial Citations
    1
    Background Citations
    3
    Methods Citations
    1

    Topics from this paper

    Explore Further: Topics Discussed in This Paper

    9 Citations
    Citation Type

    Citation Type

    Predisposición genética para el cáncer de mama: genes BRCA1 y BRCA2
    • 8
    • PDF
    Effective preventive treatments for hereditary breast cancer
    • Highly Influenced
    Guidelines for complex genetic analysis of hereditary breast ovarian cancer syndrome in slovak population
    • PDF
    Radiologic Education Mammographic Parenchymal Patterns as an Imaging Marker of Endogenous Hormonal Exposure : A Preliminary Study in a High-Risk Population
    • 1
    • PDF
    Mammographic parenchymal patterns as an imaging marker of endogenous hormonal exposure: a preliminary study in a high-risk population.
    • 8
    Mammographic parenchymal texture as an imaging marker of hormonal activity: a comparative study between pre- and post-menopausal women
    • 2
    • PDF
    The influence of genetic factors on brain plasticity and recovery after neural injury.
    • 27
    DCPIP (2,6-dichlorophenolindophenol) as a genotype-directed redox chemotherapeutic targeting NQO1*2 breast carcinoma
    • 12
    Clinical classification of BRCA1 DNA missense variants: H1686Q is a novel pathogenic mutation occurring in the ontogenetically invariant THV motif of the N-terminal BRCT domain.
    • G. Giannini, C. Capalbo, +13 authors A. Gulino
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2008
    • 14

    References

    SHOWING 1-10 OF 56 REFERENCES
    Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2
    • 1,490
    Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies
    • 141
    • PDF
    Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
    • 648
    • PDF
    Cancer Susceptibility and the Functions of BRCA1 and BRCA2
    • 1,484
    • PDF
    Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
    • T. Rebbeck, T. Friebel, +10 authors B. Weber
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2004
    • 666
    • PDF
    Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers.
    • 687
    Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
    • 220
    The role of BRCA1 in the cellular response to chemotherapy.
    • 384
    • PDF
    Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.
    • A. Eisen, J. Lubiński, +17 authors S. Narod
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2005
    • 438
    Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study.
    • 93
    • PDF